



Shareholder Presentation

ANNUAL GENERAL MEETING | 29TH NOVEMBER 2024

Confidential – Do not duplicate or distribute without the written permission of Advanced Health Intelligence Ltd

This presentation (“Presentation”) has been prepared by **Advanced Health Intelligence Ltd** (“Advanced Health Intelligence” or “Company”).

You must read and accept the conditions in this notice before considering the information set out in or referred to in this Presentation. If you do not agree, accept or understand the terms on which this Presentation is supplied, or if you are subject to the laws of any jurisdiction in which it would be unlawful to receive this Presentation or which requires compliance with obligations that have not been complied with in respect of it, you must immediately return or destroy this Presentation and any other confidential information supplied to you by Advanced Health Intelligence. By accepting this document, you acknowledge and agree to the conditions in this notice and agree that you irrevocably release Advanced Health Intelligence from any claims you may have (presently or in the future) in connection with the provision or content of this Presentation.

NO OFFER

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction (and will not be lodged with the ASIC).

This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire shares of Advanced Health Intelligence and does not and will not form any part of any contract for the acquisition of shares of Advanced Health Intelligence.

SUMMARY INFORMATION

This Presentation contains summary information about Advanced Health Intelligence, its subsidiaries and their activities which is current as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Advanced Health Intelligence or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act. While Advanced Health Intelligence has taken every effort to ensure the accuracy of the material in the presentation, neither the Company nor its advisers have verified the accuracy or completeness of the information, or any statements and opinion contained in this Presentation.

NOT INVESTMENT ADVICE

Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Advanced Health Intelligence and the impact that different future outcomes may have on Advanced Health Intelligence.

This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. Advanced Health Intelligence is not licensed to provide financial product advice in respect of Advanced Health Intelligence shares.

Cooling off rights do not apply to the acquisition of Advanced Health Intelligence shares.

INVESTMENT RISK

An investment in Advanced Health Intelligence shares is subject to known and unknown risks, some of which are beyond the control of Advanced Health Intelligence. Advanced Health Intelligence does not guarantee any particular rate of return or the performance of Advanced Health Intelligence nor does it guarantee any particular tax treatment. An investment in Advanced Health Intelligence should be considered as Highly Speculative and High Risk due to the start up nature of the Company and its proposed business.

FINANCIAL DATA

All dollar values in this Presentation are in Australian dollars (A\$ or AUD) unless otherwise stated.

FORWARD-LOOKING STATEMENTS

This Presentation may contain forward looking statements. The words 'anticipate', 'believe', 'expect', 'project', 'forecast', 'estimate', 'likely', 'intend', 'should', 'could', 'may', 'target', 'plan' and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements are subject to risk factors associated with the Company's business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. You should not place undue reliance on forward-looking statements and neither Advanced Health Intelligence nor any of its directors, employees, advisers or agents assume any obligation to update such information.

DISCLAIMER

None of Advanced Health Intelligence's respective advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents, have authorized, permitted or caused the issue, submission, dispatch or provision of this Presentation and, except to the extent referred to in this Presentation, none of them makes or purports to make any statement in this Presentation and there is no statement in this Presentation which is based on any statement by any of them.

To the maximum extent permitted by law, Advanced Health Intelligence and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of your participation in an investment in Advanced Health Intelligence and the information in this Presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise.

To the maximum extent permitted by law, Advanced Health Intelligence and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation.

Statements made in this Presentation are made only as the date of this Presentation. The information in this Presentation remains subject to change without notice.

Agenda

2024 Summary

Corporate Compliance

Finance

Operations

AHI Solution

2025 Targets

Discussion



Opening remarks

Acknowledgement

AHI Board and management identify the importance and value of its key stakeholders within the company's journey through 2024 and into the future.

- Shareholders
- Commercial Partners
- Operational Partners
- AHI team

Executive summary

Advanced Health Intelligence Ltd (ASX:AHI)

Is a global digital health solution



Corporate overview

AHI sells its dHaaS (digital health-as-a-service) technology **to health care, insurance, selected enterprise and government** customer segments around the world in a business-to-business (**B-to-B**) model.

- **AHI conducts health risk stratification using only a smartphone by capturing biomarker data**, including vital signs, body composition, dimension, and indicative blood markers. In addition, AHI offers DermaScan which covers 588 skin conditions across 134 categories.
- AHI's technology enables its partners to estimate **47 health markers and 35 health risks across six categories**.
- AHI holds **patents in Australia, Europe, USA, Japan, Korea, Singapore, New Zealand, China and Canada** and is adding to the patent portfolio.
- **AHI completed two acquisitions in 2022, expanding** its capabilities to offer mass population health monitoring using only a user's smartphone.
- 2023 was dedicated to integrating the technologies, 2024 is focused on scientific **validation, regulatory certification and commercialization**.

Issuer	Advanced Health Intelligence Ltd.
Exchange	Australian Securities Exchange (ASX): AHI
Shares on issue As at 25 November 2024	269,321,900
Options	3,340,000
Performance Rights	22,150,000
Employee headcount	19 across Australia, Singapore, Canada, South Africa, Netherlands

2024 Summary



Tailwinds

1. GenAI and long language model (LLM) adoption supported healthcare willingness to adopt new technologies.
2. MedTech trust and increased CAGR
3. GLP1 adoption essalated relevance of accurate body dimension measurements.

Headwinds

1. General economic climate
2. Corporate appetite for innovation slowed with economic uncertainty.
3. Capital raising into a suspended public company

ASX, Nasdaq and Audit

- All corporate updates throughout 2024 are located at <https://www.asx.com.au/markets/company/AHI>.
- AHI has been unable to lodge timely reports for half year and full year. The FY2024 annual audit is expected to complete in December 2024.
- AHI has been unsuccessful in remediating minimum shareholder equity for Nasdaq and received notice of determination to delist, AHI has appealed the determination which remains ongoing.
- AHI Board has convened at higher cadence throughout 2024 to navigate the challenges associated with elongated suspension and are confident of the financial position now and into 2025.

ASX

- Trading halt – Feb 2024
- Voluntary suspension from quotation – Feb 2024
- SEPA financier withdrawal Feb 2024
- Involuntary suspension from quotation – Late filing of ASX Appendix 4C – March 2024
- Reinstatement criteria – April 2024 & June 2024
- Quarters academy A\$4m – October 2024
- Audit review to reassess reinstatement - pending

Nasdaq

- Notice of shareholder equity deficiency in Nov 2023.
- In March 2024 AHI was granted extension of time to regain compliance by May 2024. Remediation unsuccessful within the granted period.
- Hearing held in June 2024 with Nasdaq Hearings Panel, presented amended compliance plan conditional to ASX reinstatement, therefore ongoing suspension.
- Determination to delist from Nasdaq in July 2024
- Appeal submitted during August 2024 – response remains open and ongoing pending ASX reinstatement

Annual Audit (FY2024)

- Yet to be completed
- Late start due to capital and challenges with independent investment valuations
- Projected completion in mid-late December 2024

Financing

AHI has pursued various financing partners throughout 2023/24. A late withdrawal from financier in January led to a halt, which impacted timely filing of the 30 December 2023 quarterly report and resulted in ASX trading suspension the company has been unsuccessful with reinstatement.

Since September 2024, AHI have engaged new financiers that have engaged with the company vision and have completed successful placements with plans for additional investments to satisfy ASX requirements for reinstatement to trading.

NOT CONCLUDED

Standby Equity Purchase Agreement (SEPA)
withdrawal Jan 2024

Oakley Capital – remain mandated

Obsidian Global Partners – pending shareholder
vote

COMPLETED

A\$4m agreement Quarters Academy Sdn Bhg,

- Completed October 2024

A\$1.9m aggregate private equity placements

- Since last AGM

IN PROCESS

**Settlement of Balance of A\$15m Funding
Package**

- Announced April 2024

Capital Management

Throughout 2024, AHI has worked to optimize use of its scarce capital by reducing operational expenditure.

- ✓ Shifting to more digital and cost-effective marketing strategies (e.g., organic social media, SEO).
- ✓ Reduction in conferences, travel and roadshows.
- ✓ Reduction in facilities costs through transitioning more staff to remote work.
- ✓ Position restructures and transferring to contractor for selected functions.
- ✓ Leveraging automation and technology to improve efficiency and reduce labour costs.
- ✓ Streamlining financial operations to avoid unnecessary fees or penalties.
- ✓ Entering payment plans with extended creditors.
- ✓ Reductions continue past 30 September 2024 into 2025.

Operating Activities Expenditure (AUD)	30 Sep 2023	30 Sep 2024	% change
Product manufacturing and operating activities	(15)	-	↓ 100%
Advertising and marketing, Leased assets	(156)	(89)	↓ 44%
Staff costs	(1,547)	(1264)	↓ 18%
Administrative and corporate costs	(1,289)	(681)	↓ 47%
Interest and other finance costs	(64)	(15)	↓ 8%
Total Quarterly Expenditure	(3,071)	(2,049)	↓ 33%

Figures from filed Quarterly Appendix 4C reports
Excl payment arrangements

2024 Operations

Our Solutions

Promote early-risk detection and encourage earlier intervention to improve health outcomes

Digital biomarker assessments are self administered, quickly and easily, from a user's own smartphone or webcam.

No supporting equipment or health professional is required, and no need for blood draws or invasive procedures.

Users receive a comprehensive report that can be shared with health professionals as desired.

License-holders receive anonymized individual and population-level data to inform decision-making.



Digital Health Check

1 Predicts 16 risks related to **weight, blood pressure, heart rate, cholesterol, and cardiac profile**, in <2 minutes.



Digital Health Assessment

2 Estimates 23 levels and associated risk related to **metabolic, cardiovascular and mental health**, by analyzing 47 health markers and 35 health risks in <15 minutes.



BodyScan[^]

3 Measures and analyses **body composition and dimension** to predict risk of obesity, metabolic syndrome and diabetes.



Cardio Check*

4 Detects **14 heart arrhythmias** including atrial fibrillation through advanced heart rhythm monitoring. **FDA cleared (K232804) with ECG equivalence. - PENDING LAUNCH.**



DermaScan*

5 **Class 1 medical device** that detects **588 skin disorders** in 134 categories, from common rashes to cancer, providing a valuable second opinion for practicing physicians.

[^] Data processed on-device: no images or videos transmitted

* In development

Product and IP

NEW SOLUTIONS:

Digital Health Check

Quick and convenient risk estimates for vital signs and health risks from a laptop, tablet, smartphone or kiosk in less than two minutes.




- **Health vitals:** Oxygen saturation levels, heart rate, blood pressure
- **Health risks:** Blood pressure risk status, Resting heart rate risk status, Oxygen saturation level, BMI risk status, LDL cholesterol risk status, HDL cholesterol risk status, Triglycerides risk status, Total cholesterol risk status, 10-year CVD risk status, Framingham score risk status, Cardiorespiratory fitness, Arterial pressure, Metabolic syndrome risk status

PENDING SOLUTION: - AF Scan (FDA). Q1-2025.

NEW PATENTS:

1. US patent application No. 12,125,582 from the US Patent Office for innovative technology in medical treatment "Predicting User Body Volume to Manage Medical Treatment".
2. EPC patent application No. 15864375.9 from the European Patent Office for innovative technology in imaging the human body, covering DermaScan, Cardio-Check, and Digital Health Assessment



Validation study

- **AHI is rapidly closing the gap to blood-based point-of-care testing**
- **Early results from first pool of subjects comparing AHI's BHA accuracy to clinical standard measurements.**

Study methodology

Objective: Evaluate risk classification performance of AHI's Digital Health Assessment compared with traditional clinical measurements.

Comparators: Clinician administered tests conducted in health care facilities, including;

- Dual-energy X-ray absorptiometry (DXA) scans,
- Live blood draw,
- Anthropometry via biokineticists
- 3-lead Electrocardiogram (ECG)
- Sphygmomanometer blood pressure measurements.

Population: 120-person subject study, with an equal distribution across BMI, age, gender, and ethnicity.

Current analysis: DHA outputs from the first 21 subjects were compared for accuracy, sensitivity, and specificity vs comparators.

Health marker	AHI accuracy	Clinical Comparison
Resting heart rate	99%	3-lead ECG
Lipid accumulation product	95%	Blood draw
LDL Cholesterol	91%	Blood draw
Waist to height ratio	90%	Biokineticist measure
Metabolic syndrome	85%	Blood draw
Total Cholesterol	83%	Blood draw

Early results from the first pool of subjects in South Africa (n=21)*

***Note:** incomplete and unpublished analysis

2024 Operations

Clients and Partners

- The ongoing trading suspension has deferred client investment into integration and launches yet the AHI team remain dedicated to growing client partnerships.
- Despite slower progress with five partners throughout 2024, AHI have launched two partners and have eight in preparation/integration phases.
- New partner territories in Canada.
- Pipeline remains strong across four main categories: Telehealth, Insurance, Pharmacy, Big tech

Launched



Deferred



Integrating



New



Partner Demo

DIGITAL HEALTH ASSESSMENT



Growing Target Sectors



Health and life insurance

\$9 tn. industry,

>9% CAGR^{1,2}

Attract subscribers and enhance benefits package for recruitment and retention

Provide access to relevant, tailored options to improve health and reduce risks



Health care providers

\$11 tn. industry

9% CAGR³

Improve efficiencies by collecting information prior to scheduled appointments

Provide valuable second opinion for physicians



Large enterprise

\$55 bn. industry,

4.5% CAGR⁴

Offer coverage discounts or additional benefits tailored to risk profiles

Facilitate data-driven negotiations with insurance companies based on employee population health risk profile



Governments and Ministries of Health

\$9.8 tn⁵. industry

6.6% CAGR⁶

Facilitate research and inform policy making

Sources

1. <https://www.precedenceresearch.com/life-insurance-market>, data from 2023
2. https://www.alliedmarketresearch.com/health-insurance-market_data from 2023
3. <https://www.businesswire.com/news/home/20190625005862/en/The-11.9-Trillion-Global-Healthcare-Market-Key-Opportunities-Strategies-2014-2022---ResearchAndMarkets.com>
4. <https://www.grandviewresearch.com/industry-analysis/corporate-wellness-market>, data from 2022
5. <https://www.who.int/publications/i/item/9789240086746> data from 2021
6. <https://data-explorer.oecd.org/> - See Health Expenditure table with unit of measurement as USD, PPP converted. Industry size is calculated with latest available data across all countries. CAGR is estimated with the assumption that growth in expenditure over the past 5-7 years is representative of future growth.

Target Market Rationale

- AHI's technology is applicable globally, however to remain focused, AHI has selected its initial targeted customers within two main geographies.
- These selected regions have large populations and the lowest penetration of healthcare providers per capita (as low as 0.83 physicians per 1000 capita in Vietnam, 0.47/1000 in Indonesia compared to 4.1/1000 in Australia).
- These geographies hold a more urgent need for non-traditional healthcare services that don't require a healthcare professional to be involved as compared to traditional methods that require a GP and/or Nurse.
- AHI has secured strategic and commercial partners in MENA and SEA to prove its thesis and establish commercial foundations for a profitable business model.



AHI has been working on the ground in the UAE for two years, developing and enhancing our relationships with key players in driving the UAE's vision for an advanced and integrated health system that leverages innovation to streamline patient care, enhance outcomes and mitigate health risks.

Partner Pharmak Direct (UAE) is targeting a minimum of 100,000 chronic illness patients as paid AHI subscribers per month each in UAE and Saudi Arabia within the next 12 months.



OneClinic (Vietnam) is targeting 1,000,000 local population within 12 months of launch for paid health screening services using AHI technology. The data captured will be analysed by Vietnam's leading medical university to demonstrate efficacy for Vietnamese populations.

2025 Targets

2025 Targets

We have been inhibited throughout 2024 and have reconciled to simplicity and discipline in 2025 to focus on three main corporate objectives to achieve financial stability through cashflow breakeven.

Vision

1
**LAUNCH AT LEAST 4
COMMERCIAL PARTNERS**
BY 31 MARCH 2025

2
**CLOSE AT LEAST 2
MAJOR PIPELINE PROSPECTS**
BY 30 JUNE 2025

3
**SaMD
CERTIFICATION**
BY 31 MARCH 2025

Tailwinds

1. GenAI adoption by medical sector
2. MedTech trust and adoption in produced increased 10-year CAGR of 4.4%
3. GLP1 weight loss program prevalence.

Headwinds

1. Corporate conservatism
2. New AI regulations

Source: <https://www.futuremarketinsights.com/reports/medtech-market>

Assessing digital biomarkers using just a smartphone

No health professional or additional equipment required, not even a wearable.



Mission



Provide health monitoring access to every smartphone user globally.



Vision



Ubiquitous health monitoring

Discussion



Nick Prosser
CHAIRMAN



Scott Montgomery
CEO / DIRECTOR



Dr Katherine Iscoe
EXECUTIVE DIRECTOR



Jacqueline Yee
NON-EXECUTIVE DIRECTOR



Dato Low Koon Pow
NON-EXECUTIVE DIRECTOR



Peter Goldstein
NON-EXECUTIVE DIRECTOR



Mike Melby
NON-EXECUTIVE DIRECTOR



Simon Durack
CFO / CORPORATE SECRETARY



Vlado Bosanac
FOUNDER / HEAD OF STRATEGY

Proxy votes summary

Resolution	For		Against		Discretionary		Abstain	
	Votes (%)	Holders	Votes (%)	Holders	Votes (%)	Holders	Votes (%)	Holders
Resolution 1 Adoption Of Remuneration Report	Vote postponed							
Resolution 2 Re-election of a Director - Peter Goldstein	51,644,128 (98.72)	36	643,930 (1.23)	13	23,100 (0.04)	5	80,263	4
Resolution 3 Re-election of a Director - Dr Katherine Iscoe	34,555,528 (97.55)	35	849,313 (2.40)	16	20,200 (0.06)	4	16,966,380	4
Resolution 4 Ratification of Prior Issue of Shares Under the Prior Placement	51,090,255 (98.46)	35	776,605 (1.50)	15	23,100 (0.04)	5	1,461	3
Resolution 5 Ratification of Prior Issue of Shares to Aries Finance Pty Ltd	51,648,491 (98.58)	38	718,369 (1.37)	13	23,100 (0.04)	5	1,461	3
Resolution 6 Ratification of Prior Issue of Shares to Aries Finance Pty Ltd – Listing Rule 7.1a	51,648,491 (98.58)	38	718,369 (1.37)	13	23,100 (0.04)	5	1,461	3
Resolution 7 Ratification of Prior Issue of Shares to Alexander Severino – Listing Rule 7.1a	51,660,255 (98.61)	36	706,605 (1.35)	15	23,100 (0.04)	5	1,461	3
Resolution 8 Ratification of Prior Issue of Shares to Adrian Mudronja – Listing Rule 7.1a	51,534,969 (98.37)	33	831,891 (1.59)	18	23,100 (0.04)	5	1,461	3
Resolution 9 Ratification of Prior Issue of Shares to Kap Vista Pty Ltd	51,593,205 (98.48)	35	773,655 (1.48)	16	23,100 (0.04)	5	1,461	3
Resolution 10 Ratification of Prior Issue of Tranche 1 Shares Under the 2024 Placement – Listing Rule 7.1	51,598,205 (98.49)	36	768,655 (1.47)	15	23,100 (0.04)	5	1,461	3
Resolution 11 Ratification of Prior Issue of Tranche 1 Shares Under the 2024 Placement – Listing Rule 7.1a	51,539,969 (98.38)	34	826,891 (1.58)	17	23,100 (0.04)	5	1,461	3
Resolution 12 Ratification of Prior Issue of Tranche 2 Shares Under the 2024 Placement – Listing Rule 7.1	51,539,969 (98.38)	34	826,891 (1.58)	17	23,100 (0.04)	5	1,461	3
Resolution 13 Approval to Issue Tranche 3 Shares Under the 2024 Placement	51,012,455 (98.32)	30	847,931 (1.63)	19	23,100 (0.04)	5	7,935	4
Resolution 14 Approval to Issue Placement Options	51,182,169 (98.65)	31	669,981 (1.29)	17	31,336 (0.06)	6	7,935	4
Resolution 15 Approval to Increase Maximum Securities Under the Company's Employee Incentive Plan	49,477,450 (94.44)	32	2,890,491 (5.52)	21	23,100 (0.04)	5	380	1
Resolution 16 Approval of 7.1a Mandate	51,509,255 (98.35)	32	833,895 (1.59)	18	31,336 (0.06)	6	16,935	3

On behalf of AHI Board and Management,

Thank-you

For more information on how Advanced Health Intelligence how our technologies can help you, find out more at <https://ahi.tech>



Corporate Headquarters

Suite 5, 71-73 South Perth
Esplanade,
South Perth WA 6151
hello@ahi.tech

Other locations

Asia Pacific: Melbourne, Singapore

North America: Toronto

Europe: Amsterdam

South Africa: Cape Town